Potential IBD Therapy PTG-200 Safe, Well-tolerated in Healthy Volunteers, Phase 1 Results Show

Potential IBD Therapy PTG-200 Safe, Well-tolerated in Healthy Volunteers, Phase 1 Results Show
PTG-200, being developed by Protagonist Therapeutics in collaboration with Janssen Biotech for the treatment of moderate and severe Crohn’s disease, was found safe and well-tolerated in healthy volunteers, according to top-line results of a Phase 1 clinical trial. PTG-200 is a first-in-class peptide that works by blocking the function of interleukin-23 receptor (IL-23R), a cell receptor involved in the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *